STOCK TITAN

Sabby group discloses 9.56% Revelation Biosciences (REVB) ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Revelation Biosciences, Inc. is the subject of a Schedule 13G reporting that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 605,702 shares of its common stock, representing 9.56% of the class as of the event date of 12/31/2025. The filing shows these shares are held with shared voting and dispositive power and no sole voting or dispositive power. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Revelation Biosciences.

Positive

  • None.

Negative

  • None.

Insights

Sabby entities report a passive 9.56% stake in Revelation Biosciences.

The Schedule 13G shows Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively beneficially owning 605,702 common shares of Revelation Biosciences, equal to 9.56% of the outstanding class. All three reporting persons list zero sole voting and dispositive power and the same shared voting and dispositive power over these shares.

Because the stake is reported on a Schedule 13G rather than 13D, the group certifies that the position was not acquired to change or influence control of the company. That indicates a passive investment posture under the rules cited, although future intent would depend on any subsequent filings.

The date of the reportable event is 12/31/2025, giving investors a snapshot of ownership at that point in time. Any material changes in this 9.56% position, or a shift from a 13G to a 13D filing status in later periods, would typically be reflected in updated beneficial ownership disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SABBY MANAGEMENT, LLC
Signature:/s/ Robert Grundstein
Name/Title:COO
Date:01/20/2026
Hal Mintz
Signature:/S/ HAL MINTZ
Name/Title:HAL MINTZ
Date:01/20/2026
Sabby Volatility Warrant Master Fund, Ltd.
Signature:/s/ Harry Thompson
Name/Title: Harry Thompson
Date:01/20/2026

FAQ

How many Revelation Biosciences (REVB) shares do the Sabby entities report owning?

The filing reports that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz beneficially own a total of 605,702 shares of Revelation Biosciences common stock.

What percentage of Revelation Biosciences’ common stock is owned by the Sabby group?

The reported beneficial ownership is 9.56% of the outstanding common stock for each of Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz.

Is the Sabby stake in Revelation Biosciences reported as passive or active?

The position is reported on a Schedule 13G, and the signatories certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Revelation Biosciences.

Who are the reporting persons in the Revelation Biosciences (REVB) Schedule 13G?

The reporting persons are Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz.

What voting and dispositive powers do the Sabby entities report over their REVB shares?

Each reporting person lists 0 shares with sole voting or dispositive power and 605,702 shares with shared voting and shared dispositive power.

What is the event date for the beneficial ownership reported in this Schedule 13G for REVB?

The date of the event that triggered the Schedule 13G filing is 12/31/2025.
Rvltn Bioscnc

NASDAQ:REVBW

REVBW Rankings

REVBW Latest News

REVBW Latest SEC Filings

REVBW Stock Data

960.00k
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO